Institut National de la Santé et de la Recherche Médicale Unité 1138, Paris F-75006, France; Centre de Recherche des Cordeliers, Equipe - Immunopathology and Therapeutic Immunointervention, Paris F-75006, France; Sorbonne Universités, UPMC University Paris 06, UMR S 1138, Paris F-75006, France; Université Paris Descartes, Sorbonne Paris Cité, UMR S 1138, Paris F-75006, France; International Associated Laboratory IMPACT (Institut National de la Santé et de la Recherche Médicale, France - Indian Council of Medical Research, India), National Institute of Immunohematology, Mumbai 400012, India.
Department of Neurology, Medical Faculty, Heinrich Heine University, Moorenstr. 5, D-40225 Düsseldorf, Germany.
Trends Pharmacol Sci. 2015 Jul;36(7):419-21. doi: 10.1016/j.tips.2015.04.012. Epub 2015 May 20.
Despite promising clinical trials, intravenous immunoglobulin (IVIg) therapy in relapsing-remitting multiple sclerosis (MS) has met with uncertainties that might be attributed to small patient cohorts, heterogeneity in the patients, dose of IVIg, or the duration and window of treatment.
尽管临床试验结果很有前景，但静脉注射免疫球蛋白（IVIg）治疗复发性缓解型多发性硬化症（MS）仍存在不确定性，这些不确定性可能归因于患者数量少、患者异质性、IVIg 剂量、治疗持续时间和窗口期。
